Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients:: Not simply overestimation

被引:17
作者
Cattaneo, D
Zenoni, S
Murgia, B
Merlini, S
Baldelli, S
Perico, N
Gotti, E
Ottomano, C
Crippa, A
Remuzzi, G
机构
[1] Mario Negri Inst Pharmacol Res, Osped Riuniti Bergamo, Dept Med & Transplantat, I-24125 Bergamo, Italy
[2] Osped Riuniti Bergamo, Lab Clin Anal, Bergamo, Italy
关键词
cyclosporine; immunoassays; HPLC; methods comparison;
D O I
10.1016/j.cccn.2004.12.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Immunoassays used for the measurement of cyclosporine (CsA) usually show cross-reactivity for CsA metabolites, usually resulting in unacceptable bias. Methods: To assess the performance of different immunoassays, CsA concentrations were analyzed in 132 samples using ACMIA, EMIT-VIVA, CEDIA-PLUS, and HPLC. Samples were collected from kidney transplant patients monitored with the traditional blood CsA trough level (C-0, n=73) and the new sampling at 2-h post CsA dosing (C-2, n=59). Results: Overall, the correlations between HPLC and other methods were good (r values ranging from 0.85 to 0.97). The use of C-2 concentrations to monitor CsA exposure were associated with an overall better performance of all the immunoassays as compared with C-0 values. However, none of the immunoassays agreed with the guidelines. proposed in the Lake Louis Consensus Conference. Of note, the CEDIA-PLUS was the only that provided a linear relationship with HPLC for both sampling times. A false positive case associated with ACMIA was also documented in blood samples from a patient withdrawn from CsA for I month. Conclusion: These data suggest that the performance of some of the most used immunoassays is not satisfactory, eventually leading to incorrect therapeutic decision guided by erroneous CsA monitoring. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 30 条
[1]  
BERESINI MH, 1993, CLIN CHEM, V39, P2235
[2]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[3]   From pharmacokinetics to pharmacogenomics: A new approach to tailor immunosuppressive therapy [J].
Cattaneo, D ;
Perico, N ;
Remuzzi, G .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (03) :299-310
[4]  
CATTANEO D, 2005, THERAPY, V2, P95
[5]   Recommendations for the implementation of Neoral C2 monitoring in clinical practice [J].
Cole, E ;
Midtvedt, K ;
Johnston, A ;
Pattison, J ;
O'Grady, C .
TRANSPLANTATION, 2002, 73 (09) :S19-S22
[6]  
DEBRUYN CSV, 1968, CUMULATIVE SUM TESTS, P1
[7]  
Dewitte K, 2002, CLIN CHEM, V48, P799
[8]   CYCLOSPORINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN IMMUNOREGULATORY DISORDERS [J].
FAULDS, D ;
GOA, KL ;
BENFIELD, P .
DRUGS, 1993, 45 (06) :953-1040
[9]  
Gaspari F, 1997, J AM SOC NEPHROL, V8, P647
[10]   Optimization of cyclosporine therapy in the Neoral era: Abbreviated AUC, single blood sampling? [J].
Gaspari, F ;
Caruso, R ;
Cattaneo, D ;
Perico, N ;
Remuzzi, G .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) :3117-3119